Maibach et al. have proposed to label activation markers and/or effector molecules when it comes to the prognostic value of CD8+ TILs [3], a suggestion in-line with functional studies discriminating bystander from cancer cell-reactive CD8+ T cells. The gene discussed is CD8A; the disease is cancer.